List of Orgovyx drug patents
Orgovyx is owned by Myovant Sciences.
Orgovyx contains Relugolix.
Orgovyx has a total of 7 drug patents out of which 0 drug patents have expired.
Orgovyx was authorised for market use on 18 December, 2020.
Orgovyx is available in tablet;oral dosage forms.
Orgovyx can be used as treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent, treatment of adult patients with advanced prostate cancer.
Drug patent challenges can be filed against Orgovyx from 2024-12-18.
The generics of Orgovyx are possible to be released after 29 September, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2024
(7 months from now) | |
| US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2024
(7 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735401 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(8 months from now) | |
| US10350170 | MYOVANT SCIENCES | Solid preparation |
Feb, 2036
(12 years from now) | |
| US10786501 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
| US10449191 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
| US11583526 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 2024-12-18
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL
ORGOVYX family patents
23
United States
11
Japan
9
European Union
6
Australia
5
China
5
Canada
5
Israel
4
Brazil
4
New Zealand
4
Mexico
3
Morocco
3
Argentina
3
EA
2
Spain
2
Denmark
2
Poland
2
Norway
2
Portugal
2
Taiwan
2
Lithuania
2
Slovenia
2
Hungary
1
Hong Kong
1
Malaysia
1
Moldova, Republic of
1
RS
1
Russia
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Netherlands
1
South Africa
1
Colombia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic